CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for China Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

China Pharmaceuticals, Inc.
24th Floor, Building A
Zhengxin Mansion, No. 5 of 1st Gaoxin Rd
Phone: +86 2984067215p:+86 2984067215 XI'AN, 710075  China
On 5/13/2015, the U.S. Securities and Exchange Commission revoked the registration of each class of registered securities of China Pharmaceuticals, Inc. for failure to make required periodic filings with the Commission.
This company is no longer actively traded on any major stock exchange.
Business Summary
China Pharmaceuticals, Inc. (CFMI) is engaged in the research, development, manufacture, packaging, marketing and distribution of pharmaceutical and medical products in the People's Republic of China (PRC) for human use for a variety of diseases and conditions. All of its operations are conducted in the PRC where its two manufacturing facilities are located, one in Xixiang County in Hanzhong and one in Xi’an Jinghe Industrial Zone. It manufacture pharmaceutical products in the form of capsules, oral solutions, tablets, granules, syrups, medicinal teas, tincture and solutions for injection that are either small volume parenteral solutions that are freeze dried powders or parenteral solutions. Certain of the pharmaceutical products the Company manufacture are used in the treatment of viral pneumonia, hypotonicity dehydration, viral influenza and many other diseases and indications.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/201212/31/2011YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
5812 Eating places

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer GuozhuWang 46 2/12/2010 2/12/2010
President, Director GuipingZhang 43 3/29/2010 2/12/2010
Chief Financial Officer TaoLei 40 3/29/2010 2/12/2010
3 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
China QinBa Pharmaceuticals, Inc. 24TH FLR, BLDG A ZHENGXIN MANSION XIAN CITY China

Business Names
Business Name
Allstar Acquisitions Co.
China Pharmaceuticals, Inc.
China Qinba Pharmaceuticals, Inc.
Pharmaceuticals, Co.
Xi’an Development Co., Ltd.
Xi’an Qinba Pharmaceuticals, Co., Ltd.

General Information
Number of Employees: 344 (As of 12/31/2011)
Outstanding Shares: 75,237,972 (As of 6/30/2012)
Shareholders: 136
Stock Exchange: OTC
Federal Tax Id: 202638087


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023